QUATTRO-II: A multicenter randomized trial comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer: Efficacy and safety analysis

被引：0

作者：

Kotaka, M. ^{[1
]}

Bando, H. ^{[2
]}

Satake, H. ^{[3
]}

Kotani, D. ^{[4
]}

Hamaguchi, T. ^{[5
]}

Shiozawa, M. ^{[6
]}

Ikumoto, T. ^{[1
]}

Masuishi, T. ^{[7
]}

Yasui, H. ^{[8
]}

Kagawa, Y. ^{[9
]}

Oki, E. ^{[10
]}

Yamamoto, Y. ^{[11
]}

Kawakami, H. ^{[12
]}

Boku, S. ^{[13
]}

Komatsu, Y. ^{[14
]}

Taniguchi, H. ^{[7
]}

Muro, K. ^{[15
]}

Yamazaki, K. ^{[16
]}

Misumi, T. ^{[17
]}

Yoshino, T. ^{[4
]}

Kato, T. ^{[18
]}

Tsuji, A. ^{[16
]}

机构：

[1] Sano Hosp, Gastrointestinal Canc Ctr, Kobe, Japan

[2] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Japan

[3] Kochi Med Sch, Dept Med Oncol, Nankoku, Japan

[4] Natl Canc Ctr Hosp East, Kashiwa, Japan

[5] Saitama Med Univ, Int Med Ctr, Hidaka, Japan

[6] Kanagawa Canc Ctr, Dept Gastrointestinal Surg, Yokohama, Japan

[7] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Japan

[8] Kobe City Med Ctr Gen Hosp, Dept Med Oncol, Kobe, Japan

[9] Osaka Gen Med Ctr, Dept Gastroenterol Surg, Osaka, Japan

[10] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Fukuoka, Japan

[11] Univ Tsukuba, Dept Gastroenterol, Fac Med, Tsukuba, Japan

[12] Kindai Univ, Fac Med, Osakasayama, Japan

[13] Kansai Med Univ, Hirakata, Japan

[14] Hokkaido Univ Hosp, Div Canc Ctr, Sapporo, Japan

[15] Shizuoka Canc Ctr, Div Gastrointestinal Oncol, Shizuoka, Japan

[16] Shizuoka Canc Ctr, Dept Gastrointestinal Oncol, Shizuoka, Japan

[17] Natl Canc Ctr Hosp East, Dept Data Sci, Kashiwa, Japan

[18] Osaka Natl Hosp, Natl Hosp Org, Dept Surg, Osaka, Japan

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.04.205

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-149

引用

页码：S68 / S68

页数：1

共 50 条

[21] A COMPARISON OF XELIRI PLUS BEVACIZUMAB WITH FOLFIRI PLUS BEVACIZUMAB AS FIRST-LINE SETTING IN PATIENTS WITH METASTATIC COLORECTAL CANCER
Ahmet, Bilici
Uygun, Kazim
Kaya, Serap
Ustaalioglu, Bala Basak Oven
Yildiz, Ramazan
Temiz, Suleyman
Seker, Mesut
Aksu, Gorkem
Cabuk, Devrim
Gumus, Mahmut
ANNALS OF ONCOLOGY, 2012, 23 : 98 - 99
[22] PHASE II STUDY OF BEVACIZUMAB plus OXALIPLATIN PLUS CAPECITABINE FOLLOWED BY BEVACIZUMAB plus ERLOTINIB AS FIRST-LINE TREATMENT IN METASTATIC COLORECTAL CANCER
Munoz, A.
Pericay, C.
Llorente, B.
Alonso, V
Duenas, R.
Roca, J.
Rivera, F.
Falco, E.
Alvarez, I
Salud, A.
ANNALS OF ONCOLOGY, 2010, 21 : 73 - 74
[23] FOLFOXIRI/Bevacizumab Plus Nivolumab as First-Line Treatment in Metastatic Colorectal Cancer RAS/BRAF Mutated: Safety Run-In of Phase II NIVACOR Trial
Damato, Angela
Bergamo, Francesca
Antonuzzo, Lorenzo
Nasti, Guglielmo
Iachetta, Francesco
Romagnani, Alessandra
Gervasi, Erika
Larocca, Mario
Pinto, Carmine
FRONTIERS IN ONCOLOGY, 2021, 11
[24] Optimizing the Efficacy of First-Line Chemotherapy plus Bevacizumab in Metastatic Colorectal Cancer
Shaotang Li
Pan Dr Chi
BioDrugs, 2011, 25 : 43 - 50
[25] First-line treatment with bevacizumab plus capecitabine for elderly patients with metastatic colorectal cancer: BECA trial
Feliu, J.
Salut, A.
Safont, M.
Losa, F.
Garcia, C.
Bosch, C.
Escudero, P.
Lopez, R.
Bolanos, M.
Gonzalez-Baron, M.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[26] Efficacy of FOLFOXIRI versus XELOXIRI plus bevacizumab in the treatment of metastatic colorectal cancer
Cheng, Yuzhuo
Song, Weiliang
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 8 (10): : 18713 - 18720
[27] FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (MCRC): Results of the phase III randomized TRIBE trial
Loupakis, Fotios
Cremolini, Chiara
Masi, Gianluca
Lonardi, Sara
Zagonel, Vittorina
Trenta, Patrizia
Tomasello, Gianluca
Ronzoni, Monica
Ciuffreda, Libero
Zaniboni, Alberto
Tonini, Giuseppe
Buonadonna, Angela
Valsuani, Chiara
Chiara, Silvana
Carlomagno, Chiara
Boni, Corrado
Marcucci, Lorenzo
Boni, Luca
Falcone, Alfredo
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
[28] FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials
Cremolini, C.
Loupakis, F.
Masi, G.
Lonardi, S.
Granetto, C.
Mancini, M. L.
Chiara, S.
Moretto, R.
Rossini, D.
Vitello, S.
Allegrini, G.
Tonini, G.
Bergamo, F.
Tomasello, G.
Ronzoni, M.
Buonadonna, A.
Bustreo, S.
Barbara, C.
Boni, L.
Falcone, A.
ANNALS OF ONCOLOGY, 2016, 27 (05) : 843 - 849
[29] FOLFOXIRI plus bevacizumab (bev) plus atezolizumab (atezo) versus FOLFOXIRI plus bev as first-line treatment of unresectable metastatic colorectal cancer (mCRC) patients: Results of the phase II randomized AtezoTRIBE study by GONO
Cremolini, C.
Rossini, D.
Antoniotti, C.
Pietrantonio, F.
Lonardi, S.
Salvatore, L.
Marmorino, F.
Borelli, B.
Ambrosini, M.
Barsotti, G.
Di Stefano, B.
Masi, G.
Boccaccino, A.
Tamberi, S.
Tamburini, E.
Frassineti, L. G.
Simionato, F.
Fontanini, G.
Boni, L.
Falcone, A.
ANNALS OF ONCOLOGY, 2021, 32 : S1294 - S1295
[30] Safety analysis of the randomized phase II study of FOLFOXIRI plus cetuximab versus FOLFOXIRI plus bevacizumab as the first-line treatment in metastatic colorectal cancer with RAS wild-type tumors: The DEEPER trial (JACCRO CC-13)
Watanabe, Takanori
Tsuji, Akihito
Shiozawa, Manabu
Ota, Hirofumi
Satake, Hironaga
Yabuno, Taichi
Hasegawa, Junichi
Kochi, Mitsugu
Manaka, Dai
Sagawa, Tamotsu
Kotaka, Masahito
Kubota, Yutaro
Sunakawa, Yu
Sekikawa, Takashi
Nakamura, Masato
Takeuchi, Masahiro
Ichikawa, Wataru
Fujii, Masashi
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)

← 1 2 3 4 5 →